Abstract: Rain streaks in outdoor images can severely affect the performance of high-level vision tasks, such as surveillance and autonomous driving, by obscuring important image details. The ...

A comprehensive collection of 298 vendor MIB libraries compiled for use with PySNMP, sourced from the LibreNMS project's curated MIB repository. This project provides tools to compile, validate, and ...

This tool has been developed using both LM Studio and Ollama as LLM providers. The idea behind using a local LLM, like Google's Gemma-3 1B, is data privacy and low cost. In addition, with a good LLM a ...

Abstract: This article introduces a novel approach to data structure visualization through the development of a new programming language, utilizing Python’s Lex-YACC library for lexical analysis and ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Investing.com -- Recursion Pharmaceuticals (NASDAQ:RXRX) stock rose 7% Monday following positive Phase 2 trial results for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), a ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...